BAY-846

BAY-846 is a potent and selective allosteric MEK inhibitor characterized by favorable pharmacokinetics, including a long half-life and high oral bioavailability with low brain penetration. It demonstrates significant anti-tumor efficacy in preclinical studies, particularly in K-Ras mutant models like the A549 xenograft, supporting its use in oncology research targeting the MAPK pathway.